Active	Status	Sponsor type	Region	Phase	Filter
14 Active 3 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

14 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ottensmeier, Christian
HARE-40, NCT03418480: HPV Anti-CD40 RNA vaccinE	Completed	1/2	32	Europe	BNT113	University of Southampton, BioNTech SE	Human Papilloma Virus Related Carcinoma, Head and Neck Neoplasm, Cervical Neoplasm, Penile Neoplasms Malignant, Unknown Primary Tumors	11/23	01/24
CRB-601-01, NCT06603844: First-in-human Study of to Treat Patients with Advanced Solid Tumor.	Recruiting	1/2	156	Europe, US	CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody, Immune-priming single lesion SBRT	Corbus Pharmaceuticals Inc.	Solid Tumor	11/26	12/26
ModiFY, NCT05329532: Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer	Recruiting	1/2	144	Europe	Modi-1/Modi-1v, Pembrolizumab, MicronJet600™ microneedle device (NanoPass)	Scancell Ltd	Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck	04/26	06/26
NEBULA, NCT05043714: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours Initiation of trial in combination with NG-641 Sep 2021 - Sep 2021: Initiation of trial in combination with NG-641	Active, not recruiting	1	30	Europe, US	NG-641 in combination with Nivolumab	Akamis Bio, Bristol-Myers Squibb	Metastatic Cancer, Epithelial Tumor	08/24	12/24
MOAT, NCT04830592: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck	Active, not recruiting	1	36	Europe	NG-641, Pembrolizumab	Akamis Bio	Squamous Cell Carcinoma of the Head and Neck	09/24	10/24
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours	Active, not recruiting	1	198	Europe, US	NG-350A plus Pembrolizumab, KEYTRUDA®	Akamis Bio, Merck Sharp & Dohme LLC	Epithelial Tumor, Metastatic Cancer	03/25	05/25
TRACERx, NCT01888601: TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)	Active, not recruiting	N/A	814	Europe		University College, London, Cancer Research UK	Non-small Cell Lung Cancer	12/26	12/26
Cave, Judith
NERO, NCT05455424: Niraparib Efficacy in Patient With Unresectable Mesothelioma	Active, not recruiting	2	88	Europe	Niraparib Oral Product, Zejula, Active Symptom Control	University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation	Mesothelioma, Malignant	12/24	12/24
Beveridge, Michelle
NCT03109925: Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement	Recruiting	2	23	Europe	DC Lumi Bead, BTG	University Hospital Southampton NHS Foundation Trust, BTG International Inc.	Benign Prostatic Hyperplasia	06/21	06/21
SPARK, NCT05260008: Study Assessing Pain Relief After Replacement of the Knee	Terminated	2	112	Europe, Canada, RoW	ATX-101, bupivacaine hydrochloride without epinephrine	Allay Therapeutics, Inc.	Acute Postoperative Pain	01/24	01/24
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor	Active, not recruiting	2	30	Europe, US	SPI-62 dose	Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.	Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic	12/24	12/25
NU-BURST, NCT03159169: Treatment of Neck and Upper Limb Pain Using BurstDR (De Ridder) Stimulation	Terminated	N/A	17	Europe	Spinal Cord Stimulation (SCS)	Abbott Medical Devices	Neck Pain, Upper Limb Pain	04/22	08/22
NCT04000659: Episealer® Knee System IDE Clinical Study	Active, not recruiting	N/A	13	Europe, Canada, US	Episealer Knee System, Microfracture	Episurf Medical Inc., MCRA	Degenerative Lesion of Articular Cartilage of Knee	06/26	06/28
Bujanova, Jana
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor	Active, not recruiting	2	30	Europe, US	SPI-62 dose	Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.	Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic	12/24	12/25